Clinical characteristics of the two cohorts used in this study
| Stage III FOLFOX or XELOX | TCGA validation | |
|---|---|---|
| Variables | n (%) | n (%) |
| n | 134 | 156 |
| Events | ||
| Deceased | 20 (14.9) | 12 (7.7) |
| Recurrence | 38 (28.4) | Ø |
| Age (years) | ||
| Mean, SD | 59.6 (11.3) | 65.9 (13.4) |
| Gender | ||
| Male | 80 (59.7) | 76 (48.7) |
| Female | 54 (40.3) | 80 (51.3) |
| Tumour location | ||
| Right | 59 (44.0) | 79 (36.5) |
| Left | 51 (38.1) | 57 (50.5) |
| Rectal | 23 (17.2) | Ø |
| Other or unknown | 1 (0.7) | 20 (12.8) |
| Stage | ||
| II | Ø | 78 (50.0) |
| III | 134 (100.0) | 61 (39.1) |
| IV | Ø | 17 (10.9) |